Enovis shares fall nearly 5% as Q1 revenue misses estimates, guidance disappoints

Published 08/05/2025, 11:34
Enovis shares fall nearly 5% as Q1 revenue misses estimates, guidance disappoints

NEW YORK - Enovis Corporation (NYSE:ENOV) reported first-quarter results that fell short of analyst expectations on the top line, while providing full-year guidance below consensus on Thursday.

The company’s shares were down 4.94% % in pre-marketmarket trading following the release.

The medical technology company posted adjusted earnings per share of $0.81, beating the analyst estimate of $0.74. However, revenue of $558.83 million narrowly missed the consensus forecast of $558.9 million.

For the first quarter, Enovis saw sales grow 8.2% YoY on a reported basis and 9.3% on a comparable basis. The Reconstructive segment led growth, with sales up 11.3% to $286.3 million. Prevention & Recovery segment sales increased 5.2% to $272.6 million.

"We delivered a strong start to 2025, with first-quarter revenues and margins exceeding expectations," said Matt Trerotola, Chief Executive Officer of Enovis. "This performance reflects the strength of our business system and the discipline of our teams as we navigate a complex global environment."

Looking ahead, Enovis updated its full-year 2025 outlook, now expecting revenue between $2.22-2.25 billion, up from its prior range of $2.19-2.22 billion but still below the analyst consensus of $2.21 billion at the midpoint. The company lowered its adjusted EPS guidance to $2.95-$3.10, down from $3.10-$3.25 previously and below the $3.18 consensus estimate.

The reduced earnings outlook includes a $20 million impact from tariffs. Enovis also trimmed its adjusted EBITDA forecast to $385-395 million from $405-415 million previously.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.